Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Exact Therapeutics AS has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are split between 2 distinct examiners and 2 distinct art units. This means each pending matter is being reviewed by a different person in a different specialized group. There is no concentration of work that would allow for a unified prosecution strategy across the cases.
VU, JAKE MINH is the busiest examiner for this company, with 1 pending office action. Since there are only 2 pending office actions in total, the workload is divided equally between the 2 distinct examiners. The involvement of 2 distinct art units suggests that even with only 2 pending office actions, the company's technology in Biotechnology & Pharmaceuticals is being evaluated by different technical divisions. With 2 distinct examiners and 2 distinct art units for just 2 pending office actions, there is no overlap in the personnel or groups reviewing these cases. Practitioners must handle each of the 2 pending office actions as a completely separate matter with its own unique examiner and art unit requirements.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VU, JAKE MINH | 1 | 41.0% | +27.0% |
| NGUYEN, HIEN NGOC | 1 | 52.7% | +40.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19344192 | ULTRASOUND MEDIATED DELIVERY OF DRUGS | VU, JAKE MINH | 1d overdue |
| 19172502 | COMPOSITION FOR ULTRASOUND ABLATION | NGUYEN, HIEN NGOC | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| 3797 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19344192 | ULTRASOUND MEDIATED DELIVERY OF DRUGS | VU, JAKE MINH | 1618 | §103Other | Final Rejection | 1d overdue | Pending | Sep 29, 2025 |
| 19172502 | COMPOSITION FOR ULTRASOUND ABLATION | NGUYEN, HIEN NGOC | 3797 | §103 | Final Rejection | — | Pending | Apr 07, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialExact Therapeutics AS has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jake Minh Vu has the most, with 1 of Exact Therapeutics AS's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
